Literature DB >> 25627652

Endocrine tumours: progressive metastatic medullary thyroid carcinoma: first- and second-line strategies.

Thera P Links1, Hans H G Verbeek1, Robert M W Hofstra1, John Th M Plukker1.   

Abstract

The treatment for metastasised medullary thyroid cancer is still a topic of discussion. One of the main challenges remains to find effective adjuvant and palliative options for patients with metastatic disease. The diagnostic and treatment strategies for this tumour are discussed and possible new developments commented. Approaches that target rearranged during transfection (RET) are preferable to those that target RET downstream proteins as, theoretically, blocking RET downstream targets will block only one of the many pathways activated by RET. Combining several agents would seem to be more promising, in particular agents that target RET with those that independently target RET signalling pathways or the more general mechanism of tumour progression.
© 2015 European Society of Endocrinology.

Entities:  

Mesh:

Year:  2015        PMID: 25627652     DOI: 10.1530/EJE-14-0726

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

2.  Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.

Authors:  Anisley Valenciaga; Elizabeth G Grubbs; Kyle Porter; Paul E Wakely; Michelle D Williams; Gilbert J Cote; Vasyl V Vasko; Motoyasu Saji; Matthew D Ringel
Journal:  Thyroid       Date:  2017-12       Impact factor: 6.568

Review 3.  Selective use of vandetanib in the treatment of thyroid cancer.

Authors:  Poupak Fallahi; Flavia Di Bari; Silvia Martina Ferrari; Roberto Spisni; Gabriele Materazzi; Paolo Miccoli; Salvatore Benvenga; Alessandro Antonelli
Journal:  Drug Des Devel Ther       Date:  2015-07-03       Impact factor: 4.162

4.  Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.

Authors:  M Schlumberger; R Elisei; S Müller; P Schöffski; M Brose; M Shah; L Licitra; J Krajewska; M C Kreissl; B Niederle; E E W Cohen; L Wirth; H Ali; D O Clary; Y Yaron; M Mangeshkar; D Ball; B Nelkin; S Sherman
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

5.  Transcriptional targeting of oncogene addiction in medullary thyroid cancer.

Authors:  Anisley Valenciaga; Motoyasu Saji; Lianbo Yu; Xiaoli Zhang; Ceimoani Bumrah; Ayse S Yilmaz; Christina M Knippler; Wayne Miles; Thomas J Giordano; Gilbert J Cote; Matthew D Ringel
Journal:  JCI Insight       Date:  2018-08-23

6.  CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma.

Authors:  Thomas A Werner; Christina M Forster; Levent Dizdar; Pablo E Verde; Katharina Raba; Matthias Schott; Wolfram T Knoefel; Andreas Krieg
Journal:  Br J Cancer       Date:  2017-11-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.